Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 454.25
(-3.03%)
USD 454.25
(-3.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.3 Billion USD | -12.94% |
| 2022 | 4.3 Billion USD | 54.83% |
| 2021 | 2.78 Billion USD | -2.6% |
| 2020 | 2.85 Billion USD | 138.51% |
| 2019 | 1.19 Billion USD | 88.55% |
| 2018 | 635.15 Million USD | 415.36% |
| 2017 | 123.24 Million USD | 1140.37% |
| 2016 | 9.93 Million USD | 102.12% |
| 2015 | -468.66 Million USD | 32.31% |
| 2014 | -692.41 Million USD | 23.36% |
| 2013 | -903.44 Million USD | -38841.34% |
| 2012 | 2.33 Million USD | -97.95% |
| 2011 | 113.82 Million USD | 116.35% |
| 2010 | -696.07 Million USD | -13.48% |
| 2009 | -613.41 Million USD | -32.57% |
| 2008 | -462.7 Million USD | -10.22% |
| 2007 | -419.79 Million USD | -83.28% |
| 2006 | -229.03 Million USD | -52.82% |
| 2005 | -149.87 Million USD | 3.19% |
| 2004 | -154.8 Million USD | 41.48% |
| 2003 | -264.52 Million USD | -121.17% |
| 2002 | -119.6 Million USD | -30.28% |
| 2001 | -91.8 Million USD | -137.33% |
| 2000 | -38.68 Million USD | 2.32% |
| 1999 | -39.6 Million USD | -22.22% |
| 1998 | -32.4 Million USD | -68.75% |
| 1997 | -19.2 Million USD | 35.57% |
| 1996 | -29.8 Million USD | -12.45% |
| 1995 | -26.5 Million USD | -28.02% |
| 1994 | -20.7 Million USD | -1825.0% |
| 1993 | 1.2 Million USD | 112.0% |
| 1992 | -10 Million USD | -78.57% |
| 1991 | -5.6 Million USD | -36.59% |
| 1990 | -4.1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 1.11 Billion USD | 131.67% |
| 2024 Q2 | -3.52 Billion USD | -410.31% |
| 2024 Q1 | 1.13 Billion USD | 18.48% |
| 2023 Q1 | 779 Million USD | -24.63% |
| 2023 Q4 | 958.8 Million USD | -7.64% |
| 2023 FY | 3.75 Billion USD | -12.94% |
| 2023 Q2 | 1.02 Billion USD | 31.76% |
| 2023 Q3 | 1.03 Billion USD | 1.14% |
| 2022 Q4 | 1.03 Billion USD | -8.27% |
| 2022 Q1 | 1.04 Billion USD | 18.59% |
| 2022 Q2 | 1.1 Billion USD | 6.28% |
| 2022 FY | 4.3 Billion USD | 54.83% |
| 2022 Q3 | 1.12 Billion USD | 1.84% |
| 2021 Q1 | 887.82 Million USD | 19.04% |
| 2021 Q2 | -37.96 Million USD | -104.28% |
| 2021 Q4 | 877.7 Million USD | -16.77% |
| 2021 FY | 2.78 Billion USD | -2.6% |
| 2021 Q3 | 1.05 Billion USD | 2877.88% |
| 2020 Q1 | 720.22 Million USD | 30.6% |
| 2020 FY | 2.85 Billion USD | 138.51% |
| 2020 Q4 | 745.79 Million USD | 10.94% |
| 2020 Q3 | 672.24 Million USD | -6.38% |
| 2020 Q2 | 718.03 Million USD | -0.3% |
| 2019 FY | 1.19 Billion USD | 88.55% |
| 2019 Q1 | 276.8 Million USD | 116.73% |
| 2019 Q4 | 551.46 Million USD | 455.17% |
| 2019 Q3 | 99.33 Million USD | -63.2% |
| 2019 Q2 | 269.96 Million USD | -2.47% |
| 2018 Q2 | 172.87 Million USD | 34.12% |
| 2018 Q4 | 127.72 Million USD | -37.89% |
| 2018 FY | 635.15 Million USD | 415.36% |
| 2018 Q1 | 128.9 Million USD | 2.52% |
| 2018 Q3 | 205.64 Million USD | 18.96% |
| 2017 Q3 | -326.04 Million USD | -718.6% |
| 2017 Q2 | 52.7 Million USD | -80.54% |
| 2017 Q1 | 270.84 Million USD | 583.25% |
| 2017 Q4 | 125.73 Million USD | 138.56% |
| 2017 FY | 123.24 Million USD | 1140.37% |
| 2016 Q2 | 3.35 Million USD | 123.4% |
| 2016 FY | 9.93 Million USD | 102.12% |
| 2016 Q1 | -14.33 Million USD | 74.17% |
| 2016 Q3 | -21.72 Million USD | -747.99% |
| 2016 Q4 | 39.64 Million USD | 282.45% |
| 2015 Q4 | -55.48 Million USD | 20.76% |
| 2015 Q1 | -171.98 Million USD | -11.95% |
| 2015 Q2 | -171.16 Million USD | 0.48% |
| 2015 FY | -468.66 Million USD | 32.31% |
| 2015 Q3 | -70.02 Million USD | 59.09% |
| 2014 Q3 | -142.2 Million USD | 21.36% |
| 2014 Q2 | -180.83 Million USD | 16.43% |
| 2014 Q4 | -153.62 Million USD | -8.03% |
| 2014 FY | -692.41 Million USD | 23.36% |
| 2014 Q1 | -216.38 Million USD | 21.07% |
| 2013 Q3 | -134.05 Million USD | -135.47% |
| 2013 Q2 | -56.93 Million USD | 87.01% |
| 2013 Q1 | -438.28 Million USD | -465.71% |
| 2013 Q4 | -274.16 Million USD | -104.51% |
| 2013 FY | -903.44 Million USD | -38841.34% |
| 2012 Q4 | -77.47 Million USD | -7133.99% |
| 2012 Q3 | -1.07 Million USD | 90.06% |
| 2012 Q2 | -10.77 Million USD | -111.75% |
| 2012 Q1 | 91.64 Million USD | -59.07% |
| 2012 FY | 2.33 Million USD | -97.95% |
| 2011 FY | 113.82 Million USD | 116.35% |
| 2011 Q1 | -159.89 Million USD | 4.04% |
| 2011 Q2 | -165.89 Million USD | -3.75% |
| 2011 Q3 | 215.7 Million USD | 230.03% |
| 2011 Q4 | 223.9 Million USD | 3.8% |
| 2010 Q4 | -166.63 Million USD | 16.51% |
| 2010 FY | -696.07 Million USD | -13.48% |
| 2010 Q1 | -160.28 Million USD | -9.24% |
| 2010 Q2 | -169.57 Million USD | -5.8% |
| 2010 Q3 | -199.58 Million USD | -17.7% |
| 2009 Q1 | -161.89 Million USD | -14.12% |
| 2009 Q4 | -146.71 Million USD | 1.02% |
| 2009 FY | -613.41 Million USD | -32.57% |
| 2009 Q2 | -157.16 Million USD | 2.92% |
| 2009 Q3 | -148.23 Million USD | 5.68% |
| 2008 FY | -462.7 Million USD | -10.22% |
| 2008 Q1 | -98.73 Million USD | -7.62% |
| 2008 Q3 | -130.62 Million USD | -42.79% |
| 2008 Q2 | -91.48 Million USD | 7.35% |
| 2008 Q4 | -141.86 Million USD | -8.6% |
| 2007 Q2 | -125.62 Million USD | -41.74% |
| 2007 Q1 | -88.62 Million USD | -153.71% |
| 2007 FY | -419.79 Million USD | -83.28% |
| 2007 Q3 | -113.79 Million USD | 9.41% |
| 2007 Q4 | -91.74 Million USD | 19.37% |
| 2006 FY | -229.03 Million USD | -52.82% |
| 2006 Q4 | -34.93 Million USD | 43.77% |
| 2006 Q3 | -62.12 Million USD | 21.58% |
| 2006 Q2 | -79.22 Million USD | -50.17% |
| 2006 Q1 | -52.75 Million USD | -99.88% |
| 2005 Q4 | -26.39 Million USD | 37.87% |
| 2005 Q2 | -38.59 Million USD | 8.97% |
| 2005 Q3 | -42.48 Million USD | -10.07% |
| 2005 FY | -149.87 Million USD | 3.19% |
| 2005 Q1 | -42.4 Million USD | -4.86% |
| 2004 Q3 | -35.58 Million USD | 15.73% |
| 2004 Q2 | -42.23 Million USD | -15.56% |
| 2004 Q1 | -36.54 Million USD | 66.62% |
| 2004 FY | -154.8 Million USD | 41.48% |
| 2004 Q4 | -40.43 Million USD | -13.62% |
| 2003 Q2 | -89 Million USD | -563.43% |
| 2003 Q4 | -109.47 Million USD | -28.41% |
| 2003 Q3 | -85.25 Million USD | 4.22% |
| 2003 Q1 | 19.2 Million USD | 157.05% |
| 2003 FY | -264.52 Million USD | -121.17% |
| 2002 Q1 | -26.06 Million USD | -67.89% |
| 2002 FY | -119.6 Million USD | -30.28% |
| 2002 Q3 | -35.85 Million USD | -49.22% |
| 2002 Q4 | -33.66 Million USD | 6.1% |
| 2002 Q2 | -24.02 Million USD | 7.82% |
| 2001 Q2 | -17.44 Million USD | -13.34% |
| 2001 Q3 | -36.15 Million USD | -107.2% |
| 2001 Q1 | -15.39 Million USD | -6.9% |
| 2001 Q4 | -15.52 Million USD | 57.06% |
| 2001 FY | -91.8 Million USD | -137.33% |
| 2000 Q2 | 9.45 Million USD | 150.92% |
| 2000 FY | -38.68 Million USD | 2.32% |
| 2000 Q4 | -14.4 Million USD | 5.08% |
| 2000 Q3 | -15.17 Million USD | -260.52% |
| 2000 Q1 | -18.56 Million USD | -983.86% |
| 1999 Q2 | -10.4 Million USD | 49.02% |
| 1999 Q1 | -20.4 Million USD | -65.85% |
| 1999 FY | -39.6 Million USD | -22.22% |
| 1999 Q3 | -13.9 Million USD | -33.65% |
| 1999 Q4 | 2.1 Million USD | 115.11% |
| 1998 Q4 | -12.3 Million USD | -485.71% |
| 1998 FY | -32.4 Million USD | -68.75% |
| 1998 Q1 | -12.3 Million USD | -89.23% |
| 1998 Q2 | -9.6 Million USD | 21.95% |
| 1998 Q3 | -2.1 Million USD | 78.13% |
| 1997 Q1 | -5.6 Million USD | -1.82% |
| 1997 Q2 | -1.2 Million USD | 78.57% |
| 1997 Q4 | -6.5 Million USD | -14.04% |
| 1997 Q3 | -5.7 Million USD | -375.0% |
| 1997 FY | -19.2 Million USD | 35.57% |
| 1996 Q2 | -8.3 Million USD | 3.49% |
| 1996 Q4 | -5.5 Million USD | 25.68% |
| 1996 FY | -29.8 Million USD | -12.45% |
| 1996 Q3 | -7.4 Million USD | 10.84% |
| 1996 Q1 | -8.6 Million USD | -273.91% |
| 1995 Q1 | -5.9 Million USD | 29.76% |
| 1995 FY | -26.5 Million USD | -28.02% |
| 1995 Q3 | -8 Million USD | 22.33% |
| 1995 Q4 | -2.3 Million USD | 71.25% |
| 1995 Q2 | -10.3 Million USD | -74.58% |
| 1994 FY | -20.7 Million USD | -1825.0% |
| 1994 Q1 | -3.2 Million USD | -137.21% |
| 1994 Q2 | -5.4 Million USD | -68.75% |
| 1994 Q4 | -8.4 Million USD | -121.05% |
| 1994 Q3 | -3.8 Million USD | 29.63% |
| 1993 FY | 1.2 Million USD | 112.0% |
| 1993 Q1 | -3.5 Million USD | -20.69% |
| 1993 Q2 | -1 Million USD | 71.43% |
| 1993 Q4 | 8.6 Million USD | 396.55% |
| 1993 Q3 | -2.9 Million USD | -190.0% |
| 1992 Q2 | -2.3 Million USD | -9.52% |
| 1992 Q1 | -2.1 Million USD | -23.53% |
| 1992 FY | -10 Million USD | -78.57% |
| 1992 Q3 | -2.6 Million USD | -13.04% |
| 1992 Q4 | -2.9 Million USD | -11.54% |
| 1991 Q1 | 800 Thousand USD | 113.79% |
| 1991 Q4 | -1.7 Million USD | -21.43% |
| 1991 FY | -5.6 Million USD | -36.59% |
| 1991 Q3 | -1.4 Million USD | -7.69% |
| 1991 Q2 | -1.3 Million USD | -262.5% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 Q2 | 600 Thousand USD | 20.0% |
| 1990 Q4 | -5.8 Million USD | -1066.67% |
| 1990 Q3 | 600 Thousand USD | 0.0% |
| 1990 FY | -4.1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 2646.09% |
| Dynavax Technologies Corporation | -37.02 Million USD | 11733.088% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 81851.756% |
| Perrigo Company plc | 151.9 Million USD | -2735.747% |
| Illumina, Inc. | -1.06 Billion USD | 502.947% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 37.199% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 1035.276% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 130.602% |
| IQVIA Holdings Inc. | 1.97 Billion USD | -117.881% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 3994.137% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | -6.434% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 9743.585% |
| Waters Corporation | 817.67 Million USD | -426.798% |
| Biogen Inc. | 1.29 Billion USD | -232.164% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 1672.052% |
| Evolus, Inc. | -49.23 Million USD | 8849.213% |
| Adicet Bio, Inc. | -152.03 Million USD | 2933.173% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 3645.413% |
| bluebird bio, Inc. | -244.26 Million USD | 1863.475% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 2868.975% |
| FibroGen, Inc. | -281.81 Million USD | 1628.485% |
| Agilent Technologies, Inc. | 1.35 Billion USD | -219.074% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 9655.807% |
| Homology Medicines, Inc. | -48.25 Million USD | 9026.536% |
| Geron Corporation | -193.94 Million USD | 2321.002% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 1626.535% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 5961.023% |
| Myriad Genetics, Inc. | -123.7 Million USD | 3582.215% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4372.169% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 935.935% |
| Zoetis Inc. | 3.06 Billion USD | -40.355% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 9036.722% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -296.171% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -2115.325% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 11101.711% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 1317.737% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 1660.654% |
| Verastem, Inc. | -92.08 Million USD | 4777.794% |
| Nektar Therapeutics | -137.42 Million USD | 3234.437% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 1958.083% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 4524.438% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 1708.332% |
| OPKO Health, Inc. | -157.02 Million USD | 2843.264% |
| Exelixis, Inc. | 170.88 Million USD | -2420.701% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -1616.819% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -3915.119% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 7825.626% |
| uniQure N.V. | -282.87 Million USD | 1622.779% |
| Imunon, Inc. | -21.03 Million USD | 20582.225% |
| Blueprint Medicines Corporation | -486.27 Million USD | 985.812% |
| Insmed Incorporated | -709.62 Million USD | 707.01% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -1176.017% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 1200.292% |
| TG Therapeutics, Inc. | 20.63 Million USD | -20776.751% |
| Incyte Corporation | 620.52 Million USD | -594.17% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 692.993% |